Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 4867-4876

  Dubovsky, Jason A ^a   Flynn, Ryan ^b   Du, Jing ^b   Harrington, Bonnie K ^c   Zhong, Yiming ^a   Kaffenberger, Benjamin ^a   Yang, Carrie ^a   Towns, William H ^a   Lehman, Amy ^a   Johnson, Amy J ^a   Muthusamy, Natarajan ^a   Devine, Steven M ^a   Jaglowski, Samantha ^a   Serody, Jonathan S ^d   Murphy, William J ^e   Munn, David H ^f   Luznik, Leo ^g   Hill, Geoffrey R ^h   Wong, Henry K ^a   MacDonald, Kelli K P ^h   Maillard, Ivan ⁱ   Koreth, John ^j   Elias, Laurence ^k   Cutler, Corey ^j   Soiffer, Robert J ^j   Antin, Joseph H ^j   Ritz, Jerome ^j   Panoskaltsis Mortari, Angela ^b   Byrd, John C ^a   Blazar, Bruce R ^b   more..

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k PHARMACYCLICS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BRUTON TYROSINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IBRUTINIB; INTERLEUKIN 2; INTERLEUKIN 2 INDUCIBLE T CELL KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; BRONCHIOLITIS OBLITERANS; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENGRAFTMENT; EPIDERMIS HYPERPLASIA; GERMINAL CENTER; HAIR LOSS; IMMUNOGLOBULIN DEPOSITION; LUNG FUNCTION; LUNG INFILTRATE; LUNG PARENCHYMA; LUNG RESISTANCE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PATHOGENESIS; PROGRESSION FREE SURVIVAL; SCLERODERMA; SKIN DEFECT; SKIN FIBROSIS; SKIN MANIFESTATION; SKIN REDNESS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE ACTIVATION;

ANIMALS; DISEASE-FREE SURVIVAL; DRUG EVALUATION, PRECLINICAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; MICE, INBRED C57BL; PYRAZOLES; PYRIMIDINES;

EID: 84908656083     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75328     Document Type: Article

References (61)

1. Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol. 2006;13(6):426-435.
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graftversus- host disease. Biol Blood Marrow Transplant. 2003;9(4):215-233.
3. Pidala J, et al. Patient-reported quality of life is associated with severity of chronic graft-versushost disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651-4657.
4. Arai S, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-4249.
5. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol. 2007;20(2):281-294.
6. + T cells, the cytokines they generate, and GVHD: Something old and something new. Blood. 2011;117(12):3268-3276.
7. Srinivasan M, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570-1580.
8. + T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease. Immunol Invest. 2014;43(1):41-53.
9. Fujii H, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: A report from the Children's Oncology Group. Blood. 2008;111(6):3276-3285.
10. Sarantopoulos S, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107-6114.
11. Sarantopoulos S, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versushost disease. Blood. 2009;113(16):3865-3874.
12. She K, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(4):386-397.
13. Carlson MJ, West ML, Coghill JM, Panoskaltsis- Mortari A, Blazar BR, Serody JS. In vitrodifferentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009;113(6):1365-1374.
14. + T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol. 2007;179(5):3305-3314.
15. + T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010;184(2):764-774.
16. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. Tec family kinases in T lymphocyte development and function. Annu Rev Immunol. 2005;23:549-600.
17. Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective. Immunol Rev. 2000;175:120-127.
18. Gomez-Rodriguez J, Kraus ZJ, Schwartzberg PL. Tec family kinases Itk and Rlk/Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J. 2011;278(12):1980-1989.
19. Schaeffer EM, et al. Mutation of Tec family kinases alters T helper cell differentiation. Nat Immunol. 2001;2(12):1183-1188.
20. Mueller C, August A. Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. J Immunol. 2003;170(10):5056-5063.
21. Au-Yeung BB, Katzman SD, Fowell DJ. Cutting edge: Itk-dependent signals required for CD4+ T cells to exert, but not gain, Th2 effector function. J Immunol. 2006;176(7):3895-3899.
22. Sahu N, et al. Selective expression rather than specific function of Txk and Itk regulate Th1 and Th2 responses. J Immunol. 2008;181(9):6125-6131.
23. + T cells. Immunity. 1999;11(4):399-409.
24. Miller AT, Wilcox HM, Lai Z, Berg LJ. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity. 2004;21(1):67-80.
25. Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13(4):R115.
26. Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
27. Dubovsky JA, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood. 2013;122(15):2539-2549.
28. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(1):9.
29. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
30. Byrd JC, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
31. Wang ML, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
32. Hamilton BL, Parkman R. Acute and chronic graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation. 1983;36(2):150-155.
33. Panoskaltsis-Mortari A, Tram KV, Price AP, Wendt CH, Blazar BR. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med. 2007;176(7):713-723.
34. Cooke KR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
35. Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
36. Numata F, Hitoshi Y, Uehara S, Takatsu K. The xid mutation plays an important role in delayed development of murine acquired immunodeficiency syndrome. Int Immunol. 1997;9(1):139-146.
37. Liu KQ, Bunnell SC, Gurniak CB, Berg LJ. T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J Exp Med. 1998;187(10):1721-1727.
38. Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93(5):578-585.
39. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009;15(9):1005-1013.
40. Teshima T, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versushost disease. Int J Hematol. 2009;90(2):253-260.
41. Tomlinson MG, Kane LP, Su J, Kadlecek TA, Mollenauer MN, Weiss A. Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec. Mol Cell Biol. 2004;24(6):2455-2466.
42. Ellmeier W, et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J Exp Med. 2000;192(11):1611-1624.
43. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol. 2011;18(6):414-420.
44. Matsuoka K, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra143.
45. Koreth J, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-2066.
46. Martino M, et al. Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: State of the art. Expert Opin Biol Ther. 2012;12(8):1017-1030.
47. Wolff D, et al. Consensus conference on clinical practice in chronic GVHD: Second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1-17.
48. Furlong T, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009;44(11):739-748.
49. Apisarnthanarax N, et al. Extracorporeal photopheresis therapy in the management of steroidrefractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003;31(6):459-465.
50. Couriel DR, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130(3):409-417.
51. Johnston LJ, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11(1):47-55.
52. Olivieri A, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709-718.
53. Inamoto Y, et al. Failure-free survival after secondline systemic treatment of chronic graft-versushost disease. Blood. 2013;121(12):2340-2346.
54. Vogl UM, et al. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: A single-center experience. Transplantation. 2013;95(4):623-628.
55. Rabitsch W, et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation. 2001;71(9):1341-1343.
56. Woyach JA, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123(8):1207-1213.
57. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123(8):1229-1238.
58. Atherly LO, Lucas JA, Felices M, Yin CC, Reiner SL, Berg LJ. The Tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8+ T cells. Immunity. 2006;25(1):79-91.
59. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versus-host disease- And graft-versusleukemia- causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol. 1998;160(11):5355-5365.
60. Blazar BR, et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer. Blood. 1998;92(10):3949-3959.
61. Lapalombella R, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694-708.